Docket No. 17008DIV5CON3(AP) Serial No. 10/087,867 Conf. No. 9687



and one or more of the hydrogen or carbon radicals in said hydrocarbyl radical may be substituted with oxygen, sulfur, nitrogen, phosphorus or halogen; R₁, R₂ and R₃ are selected from the group consisting of hydroxy, hydrocarbyloxy and heteroatom substituted hydrocarbyloxy wherein said hydrocarbyl radical comprises up to 20 carbon atoms; Y represents 2 hydrogen radicals or an oxo radical and X represents a hydroxyl, a hydrocarbylcarboxy, a hydrocarbyloxy, an amino or a mono or dialkyl amino radical; provided, however, at least one of R₁, R₂ and R₃ is a hydrocarbyloxy or heteroatom substituted hydrocarbyloxy radical.

REMARKS

The Examiner has rejected claim 1 under 35 USC 102(b) as being anticipated by Floyd. After interviewing, the Examiner, applicant's attorney agreed to delete the treatment of "renal dysfunction" from claim 1 to overcome this rejection. It is believed that claim 1, as amended, is now in condition for allowance.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Respectfully Submitted

Allergan, Inc. ROBERT J. BARAN (T2-7H) 2525 Dupont Drive Irvine, CA 92612-1599 Robert J. Baran Registration No. 25,806 Telephone:714/246-4669 Telecopier:714/246-4249

CERTIFICATE OF MAILING
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED
STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: BOX AMENDMENT-FINAL-NON FEE, ASSISTANT COMMISSIONER FOR
PATENTS, WASHINGTON, D.C. 20231 ON

PATENTS OF THE PROPERTY OF